IMPC phenotypes (gene matching)
STOCK B2mtm1Unc H2-Ab1b-tm1Doi Tg(Cd4-EGFP) Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma/Orl
| Status | Available to order |
| EMMA ID | EM:05922 |
| International strain name | STOCK B2mtm1Unc H2-Ab1b-tm1Doi Tg(Cd4-EGFP) Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma/Orl |
| Alternative name | Sure-L1/CD4-EGFP |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Cd4-EGFP)1Lt, Tg(HLA-DRA*0101, HLA-DRB1*0101)1Dma, Tg(HLA-A/H2-D/B2M)1Bpe, H2-Ab1b-tm1Doi |
| Gene/Transgene symbol | Tg(Cd4-EGFP)1Lt, Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma, Tg(HLA-A/H2-D/B2M)1Bpe, H2-Ab1, B2m |
Information from provider
| Provider | Yu Chun LONE |
| Provider affiliation | INSERM U1014 |
| Genetic information | A transgenic construct containing an enhanced green florescent protein cDNA fused to the murine Cd4 promoter as described by Reifsnyder P. et al. (PubMed: 10570176) was injected into Sure-L1 (EM:01783) mouse eggs. Founder line was then mated to Sure-L1 mice until homozygous. |
| Phenotypic information | Sure-L1/Cd4-EGFP |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | yes |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
| Animals used for archiving | homozygous 0, homozygous 0 |
| Breeding at archiving centre | Transgenic for CD4; homozygote KO for IAbeta, Rag2 and GammaC; heterozygote for Beta2m. |
| Stage of embryos | 2-cell |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Immunodeficiency by defective expression of MHC class I / Orphanet_34592
- Variant ABeta2M amyloidosis / Orphanet_314652
MGI phenotypes (allele matching)
- decreased level of surface class I molecules / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased IgG level / MGI
- abnormal pancreas morphology / MGI
- decreased susceptibility to bacterial infection / MGI
- increased IgM level / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased circulating serum albumin level / MGI
- increased T-helper 1 cell number / MGI
- abnormal interleukin level / MGI
- abnormal tumor necrosis factor level / MGI
- increased susceptibility to infection induced morbidity/mortality / MGI
- absent CD8-positive, alpha-beta T cells / MGI
- abnormal pancreatic beta cell morphology / MGI
- abnormal T cell number / MGI
- insulitis / MGI
MGI phenotypes (gene matching)
- absent CD8-positive, alpha-beta T cells / MGI
- decreased IgG level / MGI
- decreased level of surface class I molecules / MGI
- abnormal pancreas morphology / MGI
- decreased susceptibility to bacterial infection / MGI
- abnormal CD8-positive, alpha-beta cytotoxic T cell morphology / MGI
- increased IgM level / MGI
- insulitis / MGI
- abnormal lateral geniculate nucleus morphology / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to parasitic infection / MGI
- abnormal cytotoxic T cell physiology / MGI
- abnormal pancreatic beta cell morphology / MGI
- decreased circulating serum albumin level / MGI
- hemochromatosis / MGI
- abnormal T cell number / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- increased T-helper 1 cell number / MGI
- increased gamma-delta T cell number / MGI
- increased gamma-delta intraepithelial T cell number / MGI
- increased tumor necrosis factor secretion / MGI
- increased interleukin-3 secretion / MGI
- decreased interleukin-4 secretion / MGI
- abnormal interleukin level / MGI
- abnormal tumor necrosis factor level / MGI
- increased susceptibility to infection induced morbidity/mortality / MGI
- abnormal immune system morphology / MGI
- abnormal spleen morphology / MGI
- abnormal immune system cell morphology / MGI
- hemolytic anemia / MGI
- postnatal growth retardation / MGI
- abnormal immune system physiology / MGI
- abnormal humoral immune response / MGI
- decreased IgG level / MGI
- decreased IgM level / MGI
- autoimmune response / MGI
- reduced fertility / MGI
- premature death / MGI
- abnormal T cell differentiation / MGI
- no abnormal phenotype detected / MGI
- abnormal spleen periarteriolar lymphoid sheath morphology / MGI
- abnormal spleen marginal zone morphology / MGI
- abnormal dendritic cell physiology / MGI
- abnormal CD4-positive, alpha beta T cell morphology / MGI
- abnormal T cell physiology / MGI
- abnormal dendritic cell antigen presentation / MGI
- abnormal B cell physiology / MGI
- abnormal immunoglobulin level / MGI
- increased IgM level / MGI
- abnormal immune system organ morphology / MGI
- increased urine protein level / MGI
- abnormal cytokine secretion / MGI
- abnormal artery development / MGI
- abnormal response/metabolism to endogenous compounds / MGI
- absent CD4-positive, alpha beta T cells / MGI
- abnormal lymphocyte physiology / MGI
- insulitis / MGI
- increased anti-double stranded DNA antibody level / MGI
- increased anti-single stranded DNA antibody level / MGI
- increased anti-erythrocyte antigen antibody level / MGI
- decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
- decreased susceptibility to experimental autoimmune myasthenia gravis / MGI
- decreased regulatory T cell number / MGI
- increased B cell number / MGI
- decreased susceptibility to parasitic infection / MGI
- increased susceptibility to parasitic infection / MGI
- abnormal level of surface class II molecules / MGI
- increased double-negative T cell number / MGI
- decreased susceptibility to autoimmune disorder / MGI
- cardiovascular system phenotype / MGI
- immune system phenotype / MGI
- abnormal CD4-positive, alpha-beta T cell physiology / MGI
- abnormal response to transplant / MGI
- increased CD4-positive, alpha beta T cell number / MGI
- decreased CD4-positive, alpha beta T cell number / MGI
- increased CD8-positive, alpha-beta T cell number / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased single-positive T cell number / MGI
- abnormal spleen B cell follicle morphology / MGI
- absent spleen germinal center / MGI
- decreased IgG1 level / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interleukin-12 secretion / MGI
- abnormal lymph node cell ratio / MGI
- abnormal neuron proliferation / MGI
Literature references
- A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
- A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo.;Manjunath N, Shankar P, Stockton B, Dubey P D, Lieberman J, von Andrian U H, ;1999;Proceedings of the National Academy of Sciences of the United States of America;96;13932-7; 10570176